Journal
ADVANCED SCIENCE
Volume 8, Issue 17, Pages -Publisher
WILEY
DOI: 10.1002/advs.202003708
Keywords
biomaterials; cell therapy; drug delivery; immunomodulation; type 1 diabetes
Categories
Funding
- National Institutes of Health (NIH) [1R01DK105967-01A1]
- Novo Nordisk Company
- Juvenile Diabetes Research Foundation (JDRF) [2-SRA-2018-472-S-B]
- Hartwell Foundation
Ask authors/readers for more resources
Islet transplantation holds promise as a curative therapy for T1D, but faces challenges like systemic immunosuppression and limited islet viability. Inducing local immunotolerance shows potential to enhance graft function, broaden therapy applicability, and reduce adverse effects of systemic immunosuppression. Interdisciplinary research involving cellular engineering, immunotherapy, and novel biomaterials is driving the development of new combinatorial strategies for the benefit of the entire T1D population.
Islet transplantation has shown promise as a curative therapy for type 1 diabetes (T1D). However, the side effects of systemic immunosuppression and limited long-term viability of engrafted islets, together with the scarcity of donor organs, highlight an urgent need for the development of new, improved, and safer cell-replacement strategies. Induction of local immunotolerance to prevent allo-rejection against islets and stem cell derived beta cells has the potential to improve graft function and broaden the applicability of cellular therapy while minimizing adverse effects of systemic immunosuppression. In this mini review, recent developments in non-encapsulation, local immunomodulatory approaches for T1D cell replacement therapies, including islet/beta cell modification, immunomodulatory biomaterial platforms, and co-transplantation of immunomodulatory cells are discussed. Key advantages and remaining challenges in translating such technologies to clinical settings are identified. Although many of the studies discussed are preliminary, the growing interest in the field has led to the exploration of new combinatorial strategies involving cellular engineering, immunotherapy, and novel biomaterials. Such interdisciplinary research will undoubtedly accelerate the development of therapies that can benefit the whole T1D population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available